Cargando…

Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC

Patients from Asia with non-small-cell lung cancer (NSCLC) often have mutations in the epidermal growth factor receptor (EGFR) gene. While an increasing number of EGFR tyrosine kinase inhibitors (TKIs) are now available for patients with EGFR mutation-positive NSCLC, most patients inevitably develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Rong, Zhou, Jianying, Ling, Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234848/
https://www.ncbi.nlm.nih.gov/pubmed/35770234
http://dx.doi.org/10.1177/11795549221103215
_version_ 1784736169516335104
author Liu, Rong
Zhou, Jianying
Ling, Xia
author_facet Liu, Rong
Zhou, Jianying
Ling, Xia
author_sort Liu, Rong
collection PubMed
description Patients from Asia with non-small-cell lung cancer (NSCLC) often have mutations in the epidermal growth factor receptor (EGFR) gene. While an increasing number of EGFR tyrosine kinase inhibitors (TKIs) are now available for patients with EGFR mutation-positive NSCLC, most patients inevitably develop resistance to the treatment. Evidence from clinical studies suggests that treatment outcomes and resistance mechanisms vary depending on the choice of TKI therapy in the first-line setting. Hence, it is important to develop optimal treatment sequencing strategies that can provide maximum survival benefit for the patient. In this review we present clinical evidence in Asian patients with NSCLC for various EGFR TKIs, with the goal of supporting the optimization of treatment sequencing.
format Online
Article
Text
id pubmed-9234848
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-92348482022-06-28 Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC Liu, Rong Zhou, Jianying Ling, Xia Clin Med Insights Oncol Review Patients from Asia with non-small-cell lung cancer (NSCLC) often have mutations in the epidermal growth factor receptor (EGFR) gene. While an increasing number of EGFR tyrosine kinase inhibitors (TKIs) are now available for patients with EGFR mutation-positive NSCLC, most patients inevitably develop resistance to the treatment. Evidence from clinical studies suggests that treatment outcomes and resistance mechanisms vary depending on the choice of TKI therapy in the first-line setting. Hence, it is important to develop optimal treatment sequencing strategies that can provide maximum survival benefit for the patient. In this review we present clinical evidence in Asian patients with NSCLC for various EGFR TKIs, with the goal of supporting the optimization of treatment sequencing. SAGE Publications 2022-06-24 /pmc/articles/PMC9234848/ /pubmed/35770234 http://dx.doi.org/10.1177/11795549221103215 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Liu, Rong
Zhou, Jianying
Ling, Xia
Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
title Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
title_full Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
title_fullStr Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
title_full_unstemmed Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
title_short Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
title_sort optimizing patient outcomes through sequential egfr tki treatment in asian patients with egfr mutation-positive nsclc
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234848/
https://www.ncbi.nlm.nih.gov/pubmed/35770234
http://dx.doi.org/10.1177/11795549221103215
work_keys_str_mv AT liurong optimizingpatientoutcomesthroughsequentialegfrtkitreatmentinasianpatientswithegfrmutationpositivensclc
AT zhoujianying optimizingpatientoutcomesthroughsequentialegfrtkitreatmentinasianpatientswithegfrmutationpositivensclc
AT lingxia optimizingpatientoutcomesthroughsequentialegfrtkitreatmentinasianpatientswithegfrmutationpositivensclc